Skip to search formSkip to main contentSkip to account menu

cangrelor

Known as: N(6)-(2-methylthioethyl)-2-(3,3,3-trifluoropropylthio)-5'-adenylic acid monoanhydride with dichloromethylenebis(phosphonic acid), [dichloro-[[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methyl]phosphonic acid 
National Institutes of Health

Related topics

Related topics

6 relations

Narrower (1)

AR C69931MX

Broader (3)

Adenosine MonophosphatePlatelet Aggregation InhibitorsPurinergic P2Y Receptor Antagonists
analogs & derivativescangrelor tetrasodium

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Cangrelor in Older Patients Results Association Between Age and Cardiovascular Events in CHAMPION PHOENIX
Cangrelor is an adenosine diphosphate receptor antagonist designed for use in patients undergoing percutaneous coronary… 
2016
2016
The Efficacy and Safety of Cangrelor in Women Versus Men During PCI: Insights From the CHAMPION PHOENIX Trial
2015
2015
Cangrelor approved for use during coronary angioplasty.
FDA on June 22 announced the approval of cangrelor, a P2Y12 platelet inhibitor, to reduce the risk of thrombotic events in… 
2015
2015
Abstract 16894: The Effect of Cangrelor on Cardiovascular and Bleeding Events in Patients With Peripheral Artery Disease - Insights From CHAMPION PHOENIX
Background: Patients with peripheral artery disease (PAD) are high risk for adverse cardiovascular and bleeding events. In… 
2014
2014
Incidence and Impact of Stent Thrombosis During Percutaneous Coronary Intervention : Comparison of Cangrelor and Clopidogrel from the
  • 2014
  • Corpus ID: 7097097
Zone I, Abstract Zone II, Exhibition 
2014
2014
Abstract 252: Champion Phoenix Study Economic Results: Direct Hospitalization Costs of Patients Receiving Clopidogrel or Cangrelor During Percutaneous Coronary Intervention
Background: Current guidelines recommend use of antiplatelet agents (oral P2Y12 inhibitors and/or GPIIb/IIIa inhibitors) in… 
2013
2013
Bei Komplikationen während PCI: Cangrelor effektiver als Clopidogrel
Verglichen mit den oral verfügbaren Konkurrenzpräparaten zeichnet sich der Thrombozyteninhibitor Cangrelor durch seine intraven… 
2011
2011
Abstract 13354: Pharmacodynamic Effects of Cangrelor and Clopidogrel: The Platelet Function Substudy from the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition in…
2009
2009
Streamlining the design of promising clinical trials: in-vitro testing of antithrombotic regimens and multiple agonists of platelet activation
Platelets are activated in vivo by multiple agonists; however, platelet function testing in vitro has been performed… 
2009
2009
Cangrelor Is Not the New Champion
Cangrelor, an investigational intravenous agent that reversibly inhibits the platelet P2Y12 adenosine diphosphate receptor, has…